Defects in mesenchymal stem cell self-renewal and cell fate determination lead to an osteopenic phenotype in Bmi-1 null mice

Journal of Bone and Mineral Research

Volumn 25, Issue 3, 2010, Pages 640-652

  Zhang, Heng Wei ^a   Ding, Jiong ^a   Jin, Jian Liang ^a   Guo, Jian ^a   Liu, Jing Ning ^a   Karaplis, Andrew ^b   Goltzman, David ^b   Miao, Dengshun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adipogenesis; BMI 1; Gene knockout mice; Mesenchymal stem cells; Osteogenesis

Indexed keywords

ALKALINE PHOSPHATASE; BMI1 PROTEIN; COLLAGEN TYPE 1; OSTEOCALCIN; PARATHYROID HORMONE RELATED PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P16; PROTEIN P19; PROTEIN P27; SIRTUIN 1; TRANSCRIPTION FACTOR RUNX2; BMI1 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

ADIPOCYTE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DENSITY; BONE GROWTH; BONE MASS; CARTILAGE CELL; CELL COUNT; CELL CULTURE; CELL FATE; CELL FUNCTION; CELL PROLIFERATION; CELL RENEWAL; COLONY FORMING UNIT; CONTROLLED STUDY; EX VIVO STUDY; FIBROBLAST; GENE EXPRESSION; GROWTH RETARDATION; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NEWBORN; NONHUMAN; NULL ALLELE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; PHENOTYPE; PROTEIN EXPRESSION; SENESCENCE; TRABECULAR BONE; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; BONE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLIC BONE DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE AND BONES; BONE DISEASES, METABOLIC; CELL DIFFERENTIATION; CELLS, CULTURED; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; PHENOTYPE; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77953419889     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090812     Document Type: Article

References (49)

1. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991;65:753-763. (Pubitemid 121001307)
2. Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA. 2005;102: 1859-1864. (Pubitemid 40261977)
3. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991;65:737-752. (Pubitemid 121001306)
4. van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the Bmi-1 proto-oncogene. Genes Dev. 1994;8:757-769. (Pubitemid 24985778)
5. Miao D, Su H, He B, et al. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci USA. 2008;105:20309-20314.
6. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423:255-260. (Pubitemid 40852690)
7. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423: 302-305. (Pubitemid 40852701)
8. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 2005;19(12):1432-1437.
9. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 2003;425:962-967. (Pubitemid 37376927)
10. Jiang R, Xu W, Zhu W, et al. Histological type of oncogenity and expression of cell cycle genes in tumor cells from human mesenchymal stem cells. Oncol Rep. 2006;16:1021-1028.
11. Zhang X, Soda Y, Takahashi K, et al. Successful immortalization of mesenchymal progenitor cells derived from human placenta and the differentiation abilities of immortalized cells. Biochem Biophys Res Commun. 2006;351:853-859. (Pubitemid 44715863)
12. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and polycomb-group gene Bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164-168 (Pubitemid 29050921)
13. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999;13:2678-2690. (Pubitemid 29508555)
14. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2:731-737.
15. Fasano CA, Dimos JT, Ivanova NB, Lowry N, Lemischka IR, Temple S. shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell. 2007;1:87-99. (Pubitemid 46865801)
16. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147. (Pubitemid 29282067)
17. Zhang ZL, Tong J, Lu RN, Scutt AM, Goltzman D, Miao DS. Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration. Bone Marrow Transplant. 2009;43:69-81.
18. Miao D, He B, Lanske B, et al. Skeletal abnormalities in PTH-null mice are influenced by dietary calcium. Endocrinology. 2004;145:2046-2053. (Pubitemid 38402414)
19. Miao D, Bai X, Panda D, McKee M, Karaplis A, Goltzman D. Osteomalacia in HYP mice is associated with abnormal Phex expression and with altered bone matrix protein expression and deposition. Endocrinology. 2001;142:926-939. (Pubitemid 32222443)
20. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem. 2004;279:16754-16766. (Pubitemid 38509378)
21. Miao D, Scutt A. Histochemical localization of alkaline phosphatase activity in decalcified bone and cartilage. J Histochem Cytochem. 2002;50:333-340. (Pubitemid 34171058)
22. Miao D, Scutt A. Recruitment, augmentation and apoptosis of rat osteoclasts in 1,25-(OH)2D3 response to short-term treatment with 1,25-dihydroxyvitamin D3 in vivo. BMC Musculoskelet Disord. 2002;3: 16.
23. Miao D, He B, Karaplis AC, Goltzman D. Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest. 2002;109: 1173-1182. (Pubitemid 34496595)
24. Miao D, Li J, Xue Y, Su H, Karaplis AC, Goltzman D. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology. 2004;145: 3554-3562. (Pubitemid 39037534)
25. Kim HJ, Vosseler CA, Weber PC, Erl W. Docosahexaenoic acid induces apoptosis in proliferating human endothelial cells. J Cell Physiol. 2005;204:881-888. (Pubitemid 41099273)
26. Xue Y, Karaplis AC, Hendy GN, Goltzman D, Miao D. Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum Mol Genet. 2005;14:1515-1528.
27. Miao D, Tong XK, Chan GK, Panda D, McPherson PS, Goltzman D. Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem 2001;276:32204-32213. (Pubitemid 37384884)
28. Miao D, He B, Jiang Y, et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest. 2005;115:2402-2411. (Pubitemid 41266202)
29. Backesjo CM, Li Y, Lindgren U, Haldosen LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs. 2009;189:93-97. (Pubitemid 43962828)
30. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue: a quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971;80:147-154.
31. Amizuka N, Karaplis AC, Henderson JE, et al. Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol. 1996;175:166-176. (Pubitemid 26148780)
32. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89: 747-754. (Pubitemid 27516177)
33. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755-764. (Pubitemid 27516178)
34. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89:765-771. (Pubitemid 27516179)
35. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR-γ2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
36. Backesjo CM, Li Y, Lindgren U, Haldosen LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res. 2006;21:993-1002. (Pubitemid 43962828)
37. Hsieh J, Gage FH. Epigenetic control of neural stem cell fate. Curr Opin Genet Dev. 2004;14:461-469. (Pubitemid 39360292)
38. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell. 2004;118:409-418. (Pubitemid 39485661)
39. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123-1136.
40. Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004;21:843-851. (Pubitemid 39626674)
41. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP, et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 2005;19:1438-1443.
42. Oguro H, Iwama A, Morita Y, Kamijo T, van Lohuizen M, Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med. 2006;203:2247-2253. (Pubitemid 44498359)
43. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
44. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996;272:877-880. (Pubitemid 26154591)
45. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59-66. (Pubitemid 2117026)
46. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996;85:733-744. (Pubitemid 126334353)
47. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996;85:721-732. (Pubitemid 126334352)
48. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707-720. (Pubitemid 126334351)
49. Drissi H, Hushka D, Aslam F, et al. The cell cycle regulator p27kip1 contributes to growth and differentiation of osteoblasts. Cancer Res. 1999;59:3705-3711. (Pubitemid 29381876)